MVM
  • Home
  • Working with MVM
  • Portfolio
  • Exits
  • News
  • Contact Us
  • Legal Information

MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.

Team

  • Neil Akhurst Neil AkhurstNeil Akhurst
  • Eric Bednarski Eric BednarskiEric Bednarski
  • Thomas Casdagli Thomas Casdagli Thomas Casdagli
  • Kevin Cheng Kevin ChengKevin Cheng
  • Kyle Dempsey Kyle DempseyKyle Dempsey
  • Eric Fritz Eric FritzEric Fritz
  • Hugo Harrod Hugo Harrod Hugo Harrod
  • Akhilesh Pathipati Akhilesh PathipatiAkhilesh Pathipati
  • Stephen Reeders Stephen Reeders Stephen Reeders
  • Jack Tanaka Jack TanakaJack Tanaka

MVM INVESTS IN EXMOOR PHARMA


MVM led a financing of eXmoor Pharma, an expert cell and gene therapy services company.

Read more

BIOTHERANOSTICS ACQUIRED


Hologic, Inc., a global leader in women's health, announced that it has agreed to acquire Biotheranostics, Inc.

Read more

MVM WINTER 2020 NEWSLETTER


Recent updates regarding MVM team, new investments, and portfolio.

Read more

MVM INVESTS IN GT MEDICAL


MVM led the Series B financing of GT Medical Technologies, a company dedicated to improving the lives of patients with brain tumors.

Read more

VALNEVA ANNOUNCES COVID PARTNERSHIP WITH UK GOVT


UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.

Read more

MVM SUMMER 2020 NEWSLETTER


Recent updates regarding MVM team, new investments, and portfolio.

Read more

MVM INVESTS IN PARAGON 28


MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.

Read more

VALNEVA TO PARTICIPATE IN UK GOVT COVID RESPONSE


Valneva announced an agreement to provide the UK government with up to 100 million doses of its COVID-19 vaccine.

Read more

MVM INVESTS IN MDXHEALTH SA


MVM completed a growth investment in MDxHealth SA, a molecular diagnostic company that markets two proprietary, differentiated tests that optimize the care of patients with prostate cancer.

Read more

MVM INVESTS IN SKYCELL


MVM led the growth investment round in SkyCell, a company that has developed temperature-control technology to safely transport vaccines and biotechnology drugs

Read more

VALNEVA AND PFIZER ANNOUNCE COLLABORATION


Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15

Read more

MVM PARTNERS LLP CLOSES FUND V


MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

Read more

HLS ANNOUNCES HEALTH CANADA APPROVAL FOR VASCEPA®


HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

Read more

BIOTHERANOSTICS LAUNCHES "NOT ANOTHER MINUTE"


Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test

Read more

VERTOS MOTION STUDY ENROLLMENT COMPLETE


Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis

Read more

HLS RECEIVES HEALTH CANADA LICENSE FOR CSAN PRONTO


HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™

Read more

VALNEVA'S PH II LYME STUDIES COMPLETE RECRUITMENT


Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15

Read more

CHEETAH MEDICAL ACQUIRED


Baxter International Inc, a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies

Read more

MVM INVESTS IN HLS THERAPEUTICS


MVM invests in HLS Therapeutics Inc which acquires and commercializes branded pharmaceuticals in central nervous system and cardiovascular therapeutic areas for the North American market

Read more

POSITIVE RESULTS FOR VALNEVA CHIKUNGUNYA VACCINE


Valneva reports further positive results for Its Chikungunya vaccine candidate

Read more

MVM ANNOUNCES PARTIAL SALE OF ITS AMBIO HOLDING


MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc., a global leader in peptide manufacturing and development to The Carlyle Group

Read more

ALEXION TO ACQUIRE WILSON THERAPEUTICS


Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Read more
MVM
Boston
MVM Partners
Old City Hall
45 School Street
Boston MA 02108
Telephone
+1 617 383 2101
London
MVM Partners LLP
30 St George Street
London
W1S 2FH
Telephone
+44 (0)20 7557 7500

Copyright ©2006-2021 MVM Partners LLP. All rights reserved. Designed by Profission